1,691 results match your criteria Pulmonary Pharmacology and Therapeutics[Journal]


Outcomes of fibrinolytic therapy for patients with metastatic cancer and acute pulmonary embolism.

Pulm Pharmacol Ther 2019 Apr 5. Epub 2019 Apr 5.

University of Kentucky Medical Center, Lexington, KY, USA.

Introduction: Malignancy is a common cause of morbidity and mortality in the United States and around the world and the second leading cause of death in the United States. There is little data on the impact of metastatic cancer on the risk of hemorrhagic stroke or mortality among patients undergoing fibrinolytic therapy (FT) for acute PE.

Methods: Using the National Inpatient Sample (NIS) database, we extracted admissions with a primary diagnosis of acute pulmonary embolism that underwent FT from 2010 to 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.04.001DOI Listing
April 2019
1 Read

Idiopathic pulmonary fibrosis-associated cough: Mechanisms and management.

Pulm Pharmacol Ther 2019 Mar 28. Epub 2019 Mar 28.

Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK; Department of Respiratory Medicine, King's College Hospital, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.008DOI Listing
March 2019
1 Read

Implementing an interstitial lung disease clinic improves survival without increasing health care resource utilization.

Pulm Pharmacol Ther 2019 Mar 28. Epub 2019 Mar 28.

Division of Respirology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Canada. Electronic address:

Background: Multidisciplinary collaboration is the cornerstone of interstitial lung disease (ILD) care. Delayed access to specialized care is associated with worse outcome. At the same time, the economic burden of ILD is high. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.012DOI Listing
March 2019
2 Reads

Systemic treatment with resveratrol alleviates adjuvant arthritis-interstitial lung disease in rats via modulation of JAK/STAT/RANKL signaling pathway.

Pulm Pharmacol Ther 2019 Mar 28. Epub 2019 Mar 28.

The Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University, Wuxi, 214000, Jiangsu, China. Electronic address:

Interstitial lung disease (ILD) is the most common pulmonary manifestation of Rheumatoid arthritis (RA) lung disease. The mechanism of RA-ILD remains obscure and more effective treatments are still needed. Resveratrol (RSV) a phytoalexin found with anti-inflammation and antioxidant activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.011DOI Listing
March 2019
2 Reads

Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial.

Pulm Pharmacol Ther 2019 Mar 24. Epub 2019 Mar 24.

LungenClinic Grosshansdorf, Airway Research Centre North (ARCN), German Centre for Lung Research (DZL), Wöhrendamm 80, 22927, Grosshansdorf, Germany. Electronic address:

Background: There are only limited treatment options for patients with non-cystic fibrosis bronchiectasis (non-CF BE). Human neutrophil elastase (HNE) is a mediator of tissue destruction in non-CF BE. BAY 85-8501, a selective and reversible HNE inhibitor, could represent a new treatment option for this disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.009DOI Listing
March 2019
1 Read

Chronic cough in the elderly.

Pulm Pharmacol Ther 2019 Mar 23. Epub 2019 Mar 23.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.

Chronic cough is a multi-factorial syndrome commonly presenting as cough hypersensitivity in adult patients. It is a common medical condition in the communities but is more prevalent in older adults. Elderly patients (≥65 years) frequently suffer from multiple comorbidities, which may lead to more clinical heterogeneity in chronic cough and pose diagnostic and therapeutic challenges. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183029
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2019.03.010DOI Listing
March 2019
1 Read

BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.

Pulm Pharmacol Ther 2019 Mar 19. Epub 2019 Mar 19.

BELLUS Health, 275 Armand-Frappier Blvd., Laval, QC, H7V 4A7, Canada.

BLU-5937 is a small molecule that was shown to be a potent, selective and non-competitive P2X3 homotrimeric receptor antagonist. P2X3 receptors are ATP ion-gated channels located on primary afferent neurons. ATP released from damaged or inflamed tissues in the airways acts on P2X3 receptors of primary afferent neurons, triggering depolarization and action potentials that are transmitted centrally and interpreted as urge to cough. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.007DOI Listing
March 2019
1 Read

Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.

Pulm Pharmacol Ther 2019 Mar 14. Epub 2019 Mar 14.

Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA. Electronic address:

Chronic cough, or cough lasting >8 weeks, is often associated with underlying medical conditions (ie, asthma, gastroesophageal reflux disease, nonasthmatic eosinophilic bronchitis, and upper-airway cough syndrome). In some patients with chronic cough, treatment of these underlying conditions does not resolve the cough (refractory chronic cough [RCC]), or none of these conditions are present (unexplained chronic cough [UCC]). Despite appropriate medical evaluation, patients with RCC or UCC frequently experience cough persisting for many years, as there are currently no targeted pharmacological approaches approved for the treatment of these conditions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183026
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2019.03.006DOI Listing
March 2019
3 Reads

Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.

Pulm Pharmacol Ther 2019 Mar 12. Epub 2019 Mar 12.

Unit of Pharmacology, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Combining a long-acting β-agonist (LABA) with a long-acting muscarinic antagonist (LAMA) is the cornerstone to treat patients with chronic obstructive pulmonary disease (COPD). In this study we have characterized the interaction between the LAMA, tiotropium bromide, and the LABA, olodaterol, on the contractile tone of human medium bronchi and small airways. The response to a combination of tiotropium bromide and olodaterol was assessed at sub-maximal contractile tone induced by carbachol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.004DOI Listing
March 2019
1 Read

Long acting β2-agonist's activation of cyclic AMP cannot halt ongoing mitogenic stimulation in airway smooth muscle cells.

Pulm Pharmacol Ther 2019 Mar 12. Epub 2019 Mar 12.

Pulmonary Cell Research and Pneumology, Department Biomedicine & Internal Medicine, University & University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland. Electronic address:

Airway smooth muscle cell (ASMC) hyperplasia causes airway wall remodelling, which is resisting to therapy. Long acting β2-agonists (LABA) relax airway muscles, but their effect on remodelling is unclear. This study compared the anti-proliferative effect of LABA in human primary ASMC, in situations where LABA were applied before, together, or after platelet derived growth factor (PDGF-BB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.005DOI Listing
March 2019
2 Reads

Antitussive therapy: A role for levodropropizine.

Pulm Pharmacol Ther 2019 Mar 11. Epub 2019 Mar 11.

S.I.S.Me.R. Società Italiana Studi di Medicina della Riproduzione, Bologna, Italy. Electronic address:

Cough is a protective reflex that serves to clear the airways of excessive secretions and foreign matter and which sometimes becomes excessive, and troublesome to patients. Cough is one of the most common reasons why individuals seek medical attention. A range of drugs have been developed in the past with antitussive activity and different mechanisms of action, but there are still very few safe and effective treatments available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.003DOI Listing

Targeting C-fibers for peripheral acting anti-tussive drugs.

Pulm Pharmacol Ther 2019 Mar 11. Epub 2019 Mar 11.

Department of Medicine, Johns Hopkins University School of Medicine, USA. Electronic address:

Activation of vagal C-fibers is likely involved in some types of pathological coughing, especially coughing that is associated with airway inflammation. This is because stimulation of vagal C-fibers leads to strong urge to cough sensations, and because C-fiber terminals can be strongly activated by mediators associated with airway inflammation. The most direct manner in which a given mediator can activate a C-fiber terminal is through interacting with its receptor expressed in the terminal membrane. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.002DOI Listing

Why chronic cough in children is different.

Pulm Pharmacol Ther 2019 Mar 6. Epub 2019 Mar 6.

Paediatric Asthma and Cough Centre, University and Research Hospitals, Gruppo Ospedaliero San Donato, Bergamo, Italy.

Recently, there have been robust changes in our knowledge of the neurophysiology of cough and novel clinical etiologies. Specifically, cough hypersensitivity in adults and protracted bacterial bronchitis (PBB) in children have been increasingly investigated, and differences between chronic cough in children and adults have been widely reported. In young children, postinfectious cough, bronchiectasis, airway malacia, PBB, and asthma appear to be the main causes of cough; however, by adolescence, the causes of cough are more likely to become those common in adults, namely, gastroesophageal reflux, asthma, and upper airway syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.03.001DOI Listing
March 2019
7 Reads
2.937 Impact Factor

Chronic cough and obesity.

Pulm Pharmacol Ther 2019 04 25;55:84-88. Epub 2019 Feb 25.

Department of Respiratory Medicine, University Hospital Center of Toulouse, Toulouse, France; Center for Pathophysiology Toulouse Purpan, INSERM U1043, CNRS UMR 5282, Toulouse III University, Toulouse, France. Electronic address:

With respective prevalence of 13% and 9.6%, obesity and chronic cough are two common conditions worldwide. The crucial role of obesity has been highlighted in the development and progression of many respiratory diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.009DOI Listing
April 2019
4 Reads

Non-pharmacological interventions for chronic cough: The past, present and future.

Pulm Pharmacol Ther 2019 Feb 23. Epub 2019 Feb 23.

Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom; Department of Respiratory Medicine, King's College Hospital, London, United Kingdom.

Non-pharmacological interventions have been explored in people with refractory chronic cough. Normally delivered by Physiotherapists and or Speech and Language Therapists, these interventions aim to educate patients about their cough, provide them with cough suppression techniques and breathing exercises, improve vocal/laryngeal hydration and psychoeducational counselling to help them gain greater control of their cough. Six key studies have been completed over the past 12 years that have consistently found non-pharmacological interventions help to improve quality of life and reduce cough frequency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.006DOI Listing
February 2019

Aminophylline increases parasternal muscle action in awake canines.

Pulm Pharmacol Ther 2019 Feb 21. Epub 2019 Feb 21.

Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address:

The traditional theophylline bronchodilator, aminophylline, is still widely used, especially in the treatment of COPD. The effects of aminophylline on ventilation and action of the costal diaphragm have been previously defined, but other respiratory muscles - notably the chest wall, are not well determined. Therefore, we investigated the effects of aminophylline on the Parasternal intercostal, a key obligatory inspiratory muscle, examining muscle length, shortening and EMG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.004DOI Listing
February 2019
2 Reads

Precision-cut lung slices from bleomycin treated animals as a model for testing potential therapies for idiopathic pulmonary fibrosis.

Pulm Pharmacol Ther 2019 04 15;55:75-83. Epub 2019 Feb 15.

Fidelta d.o.o., Prilaz baruna Filipovića 29, 10000, Zagreb, Croatia.

Idiopathic pulmonary fibrosis (IPF) is a complex lung disease with incompletely understood pathophysiology. Effectiveness of available medicines is limited and the need for new and improved therapies remains. Due to complexity of the disease, it is difficult to develop predictable in vitro models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.005DOI Listing
April 2019
1 Read

Cough in exercise and athletes.

Pulm Pharmacol Ther 2019 04 13;55:67-74. Epub 2019 Feb 13.

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Canada.

In the general population, particularly in individuals with asthma, cough is a common symptom, often reported after exertion, although regular exercise may be associated with a reduction in the prevalence of cough. In athletes, exercise-induced cough is also a particularly frequent symptom. The main etiologies of cough in athletes are somewhat similar to non-athletes, including asthma/airway hyperresponsiveness, upper airways disorders such as allergic or non-allergic rhinitis, and exercise-induced laryngeal obstruction, although these conditions are more frequently observed in athletes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.003DOI Listing
April 2019
2 Reads

Heterogeneity of cough neurobiology: Clinical implications.

Pulm Pharmacol Ther 2019 04 11;55:62-66. Epub 2019 Feb 11.

Monash Biomedicine Discovery Institute and Department of Medical Imaging and Radiation Sciences, Monash University, Clayton, Vic, 3800, Australia.

Cough is an important protective mechanism for clearing the airways but becomes a troublesome, and often difficult to treat, symptom in respiratory disease. Although cough can be produced as a reflex in response to the presence of irritants within the airways, emerging research demonstrates an unappreciated complexity in the peripheral and central neural systems that regulate cough. This complexity includes multiple primary sensory neurons that can induce or facilitate reflex coughing, different ascending central circuits in the brain that contribute to cough sensory discrimination and the perception of the urge-to-cough, and several descending brain systems for inducing, facilitating and inhibiting cough responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.002DOI Listing
April 2019
2 Reads

Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy.

Pulm Pharmacol Ther 2019 04 7;55:50-61. Epub 2019 Feb 7.

Clinical Pharmacokinetics Laboratory, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, People's Republic of China. Electronic address:

Pulmonary delivery of anti-cancer drugs in the form of nanoparticulate dry powders is considered a promising modality for treating lung cancer. However, it is not known whether the pharmacodynamics and pharmacokinetics of nano-preparations are altered after co-spray drying. In this study, we compared the physicochemical property, anti-cancer activity, tumor targeting and pharmacokinetic behavior of docetaxel-loaded folic acid-conjugated liposomes (LPs-DTX-FA) with those of dry powder prepared by co-spray-drying LPs-DTX-FA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.02.001DOI Listing
April 2019
2 Reads

Cough in pulmonary tuberculosis: Existing knowledge and general insights.

Pulm Pharmacol Ther 2019 04 1;55:89-94. Epub 2019 Feb 1.

Department of Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK. Electronic address:

Cough is a prominent symptom of pulmonary tuberculosis (TB), one of the oldest and most prevalent infectious diseases. Coughing probably has a pivotal role in transmission of the causative organism Mycobacterium tuberculosis. Despite this, little research to date has addressed this subject. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.008DOI Listing
April 2019
7 Reads

SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension.

Pulm Pharmacol Ther 2019 04 28;55:38-49. Epub 2019 Jan 28.

Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology and Center for Human Genome Research, Huazhong University of Science and Technology, Wuhan, PR China; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA; Department of Molecular Medicine, CCLCM of Case Western Reserve University, Cleveland, OH, 44195, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA. Electronic address:

Introduction: Pulmonary arterial hypertension (PAH) is a life-threatening disease without effective therapies. PAH is associated with a progressive increase in pulmonary vascular resistance and irreversible pulmonary vascular remodeling. SUMO1 (small ubiquitin-related modifier 1) can bind to target proteins and lead to protein SUMOylation, an important post-translational modification with a key role in many diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.007DOI Listing
April 2019
3 Reads

Adrenomedullin mediates pro-angiogenic and pro-inflammatory cytokines in asthma and COPD.

Pulm Pharmacol Ther 2019 Jan 25. Epub 2019 Jan 25.

Clinic of Pulmonary Medicine and Respiratory Cell Research, University Hospital, Department of Biomedicine, University of Basel, Basel, Switzerland. Electronic address:

Purpose: Adrenomedullin (AM) is a pluripotent peptide hormone with contradictory effects in human health and disease. In chronic inflammatory lung diseases, such as asthma and COPD, AM has been shown to inhibit inflammation and cell proliferation. In the present study, we aimed to investigate the effect of AM on pro-angiogenic and pro-inflammatory cytokines in asthma and COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.006DOI Listing
January 2019
1 Read
2.937 Impact Factor

Limitations of the results from randomized clinical trials involving intravenous and nebulised magnesium sulphate in adults with severe acute asthma.

Pulm Pharmacol Ther 2019 04 17;55:31-37. Epub 2019 Jan 17.

Department of Pulmonology, University Hospital Centre Zagreb, Zagreb, Croatia. Electronic address:

The role of intravenous (IV) or nebulised magnesium sulphate (MgSO) in the treatment of severe acute asthma in adults is unclear. A controversy exists regarding its efficacy. In children MgSO has a more evident clinical effect, but the child population has not been considered in this work. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.005DOI Listing
April 2019
2 Reads

Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis.

Pulm Pharmacol Ther 2019 04 16;55:17-24. Epub 2019 Jan 16.

1st Academic Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, Hospital for Diseases of the Chest, "Sotiria", Athens, Greece; Biomedical Sciences Research Center, "Alexander Fleming", Division of Immunology, Athens, Greece. Electronic address:

Background: Vitamin D (VitD) is a steroid hormone with cytoprotective and anti-inflammatory properties. Epidemiological studies have suggested a link between VitD deficiency and risk of development of chronic lung diseases. Its role in lung fibrosis is largely unknown. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183023
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2019.01.003DOI Listing
April 2019
14 Reads

The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement.

Pulm Pharmacol Ther 2019 04 15;55:25-30. Epub 2019 Jan 15.

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Napoli, Italy.

Adiponectin (Acrp30) plays an important role in energy metabolism and inflammation. Recently, in vivo serum Acrp30 levels have been reported to be correlated to risk of developing several types of cancers such as lung cancer, and in vitro studies have demonstrated a role for Acrp30 in the control of cell proliferation and survival. However, the molecular effects of Acrp30 on lung cancer have not yet been clearly defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.004DOI Listing
April 2019
3 Reads

Alteplase and DNase for the treatment of pleural empyema in rats.

Pulm Pharmacol Ther 2019 04 14;55:1-4. Epub 2019 Jan 14.

Biomedical Engineer, Clinicas Hospital of Porto Alegre, Brazil.

Background And Objectives: Adjunctive intrapleural fibrinolytic is an option to treat empyema at fibrinopurulent stage, but there is controversy about which should be use. Our objective is to evaluate the action of alteplase and/or desoxyribonuclease at physical and chemical properties in vitro pus derived from an experimental induced empyema in rats.

Methods: Streptococcus pneumoniae was introduced into the pleural cavity by thoracentesis through pleural pressure monitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.001DOI Listing
April 2019
7 Reads

Penehyclidine effects the angiogenic potential of pulmonary microvascular endothelial cells.

Pulm Pharmacol Ther 2019 04 11;55:5-16. Epub 2019 Jan 11.

Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

The present study sought to determine the pharmacological effects of penehyclidine, an anticholinergic agent, on the angiogenic capacity of pulmonary microvascular endothelial cells (PMVECs). In vitro Matrigel network formation assay, cell proliferation assay, cell-matrix adhesion assay, and wound-healing assay were performed in PMVECs with or without exposure to penehyclidine or, in some cases, glycopyrrolate or acetylcholine, over a concentration range. In addition, the phosphorylation state of Akt and ERK, as well as the endogenous level of mTOR and RICTOR were examined in PMVECs by Western blot following the cells exposure to penehyclidine or, for some proteins, glycopyrrolate or acetylcholine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2019.01.002DOI Listing
April 2019
1 Read

GYY4137 attenuates LPS-induced acute lung injury via heme oxygenase-1 modulation.

Pulm Pharmacol Ther 2019 02 31;54:77-86. Epub 2018 Dec 31.

Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address:

GYY4137, a slow-releasing hydrogen sulfide (HS) donor, has been reported to exert anti-inflammatory activity and protect against sepsis. Heme oxygenase-1 (HO-1) is an important anti-inflammatory heat shock protein and plays a similar effect on sepsis. This study investigated the role of GYY4137 in acute lung injury (ALI) via HO-1 regulation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183009
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.12.004DOI Listing
February 2019
3 Reads

Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life.

Pulm Pharmacol Ther 2019 02 29;54:87-89. Epub 2018 Dec 29.

Allergy & Respiratory Diseases, University of Genoa, Genoa, Italy.

Mepolizumab (anti IL-5, monoclonal antibody) is commercially available in Italy since more than one year for the treatment of severe hypereosinophilic asthma. Its efficacy and safety were evaluated in several regulatory trials. The characteristics of this drug in real life began to be assessed only recently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.12.003DOI Listing
February 2019
2 Reads

Efficacy and safety of a novel nitric oxide generator for the treatment of neonatal pulmonary hypertension: Experimental and clinical studies.

Pulm Pharmacol Ther 2019 02 8;54:68-76. Epub 2018 Dec 8.

Department of Neonatology, University Hospital, Montevideo, 11600, Uruguay.

Persistent pulmonary hypertension of the newborn (PPHN) is a complex pathology resulting from a failure of the post-natal reduction in pulmonary vascular resistance leading to hypoxemia. The standard therapy is inhaled Nitric Oxide (NO) improving oxygenation but its availability is limited, especially in hospitals with restricted financial resources. We evaluated the efficacy and safety of a new device generating NO (TAS + PLUS), in three experimental piglet models of pulmonary hypertension (PH), and we later tested its application in a pilot study of newborn patients suffering from PPHN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.12.002DOI Listing
February 2019
4 Reads

Arbutin attenuates LPS-induced lung injury via Sirt1/ Nrf2/ NF-κBp65 pathway.

Pulm Pharmacol Ther 2019 02 6;54:53-59. Epub 2018 Dec 6.

The Third Affiliated Hospital of Soochow University, Changzhou, 213000, China; Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China. Electronic address:

The main goal of this study was to evaluate the effects of arbutin (AR) on lipopolysaccharide (LPS)-induced lung injury. A lung injury rat model was established by intravenous LPS administration. We found that levels of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) in both serum and lung tissue were significant increased after LPS challenge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.12.001DOI Listing
February 2019
2 Reads

The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation.

Pulm Pharmacol Ther 2019 02 28;54:60-67. Epub 2018 Nov 28.

Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Department of Pharmacology, Martin, Slovakia.

Introduction: Mucoactive agent, erdosteine, besides mucolytic activity, is characterized by many other pharmacodynamic properties which could be beneficial in the management of inflammatory conditions.

Background: Using guinea pig experimental model of allergic inflammation, we evaluated the ability of erdosteine to modulate airway defence mechanisms and inflammation after 10 days (10 mg/kg/day) administration.

Methods: In vivo changes in specific airway resistance and amplitude of tracheal contraction were estimated to evaluate the bronchodilatory effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.11.006DOI Listing
February 2019
2 Reads

Effect of mesenchymal stromal (stem) cell (MSC) transplantation in asthmatic animal models: A systematic review and meta-analysis.

Authors:
Li-Bo Zhang Min He

Pulm Pharmacol Ther 2019 02 26;54:39-52. Epub 2018 Nov 26.

Department of Respiratory Medicine, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China. Electronic address:

Background: Over the years, mesenchymal stromal (stem) cells (MSCs) have been pre-clinically applied in the treatment of variety kinds of diseases including asthma and chronic lung diseases. Aim of the current study was to systematically review and to conduct meta-analysis on the published studies of MSC treatment in asthma animal models.

Methods: Publications on the MSC and asthma treatment was thoroughly searched in the electronic databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.11.007DOI Listing
February 2019
2 Reads

Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors.

Pulm Pharmacol Ther 2019 02 15;54:31-38. Epub 2018 Nov 15.

End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease, and consequently, effective antifibrotic drugs are strongly desired. Although we have previously reported a validated Col1a1-Luc Tg rat model for fibrosis, there are only a few mouse models that enable the evaluation of fibrosis in a short time period and with high sensitivity. Therefore, we generated a Col1a1-internal ribosome entry site (IRES)-Luc knock-in (KI) mouse in which the IRES-luciferase gene construct was inserted into the 3'-UTR of the type I collagen alpha 1 gene (Col1a1). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183009
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.11.005DOI Listing
February 2019
14 Reads

Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements.

Pulm Pharmacol Ther 2019 02 14;54:1-21. Epub 2018 Nov 14.

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER-HYD), Balanagar, Telangana, 500037, India. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183018
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.11.004DOI Listing
February 2019
10 Reads

Prevalence of Arnold nerve reflex in subjects with and without chronic cough: Relevance to Cough Hypersensitivity Syndrome.

Pulm Pharmacol Ther 2019 02 13;54:22-24. Epub 2018 Nov 13.

Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.

Introduction: Cough is induced by stimulation of structures innervated by the vagus nerve, including the upper and lower airways and distal esophagus. The Arnold nerve reflex describes cough resulting from stimulation of the external auditory canal, which is innervated by the auricular branch of the vagus. We have recently reported the increased prevalence of this reflex in adults, but not children, with chronic cough, relative to healthy adult and pediatric subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.11.003DOI Listing
February 2019
2 Reads

Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.

Pulm Pharmacol Ther 2019 02 7;54:25-30. Epub 2018 Nov 7.

Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University "Magna Græcia" of Catanzaro, Italy. Electronic address:

Omalizumab is a humanized monoclonal antibody which binds to human immunoglobulins E (IgE), thus preventing their interactions with both high affinity and low affinity IgE receptors. Therefore, omalizumab is currently recommended for add-on biological therapy of uncontrolled allergic asthma, mainly characterized by type 2 airway eosinophilic inflammation. Because omalizumab has been the first, and for a long time the only available monoclonal antibody for add-on treatment of type 2 asthma, some long-term studies have been published which provide a clear evidence of the therapeutic effectiveness of the anti-IgE pharmacological strategy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183024
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.11.002DOI Listing
February 2019
13 Reads

Varenicline for long term smoking cessation in patients with COPD.

Pulm Pharmacol Ther 2018 12 3;53:116-120. Epub 2018 Nov 3.

Department of Experimental Medicine and Surgery, Chair of Respiratory Medicine, University of Rome 'Tor Vergata', Via Montpellier, 100133, Rome, Italy.

Background: Quitting smoking is key for patients with Chronic Obstructive Pulmonary Disease (COPD). Standard recommendations for quitting smoking are implemented for COPD as well. Varenicline Tartrate (VT) is the most effective drug to help quit smoking, but few studies have analysed its effectiveness. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183004
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.11.001DOI Listing
December 2018
22 Reads

Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo.

Pulm Pharmacol Ther 2018 12 28;53:100-106. Epub 2018 Oct 28.

Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou, 310013, China. Electronic address:

Background: Idiopathic pulmonary fibrosis is a lethal fibrosing interstitial pneumonia characterized by progressive worsening of dyspnea and lung function with poor prognosis. Since pirfenidone was approved for IPF treatment, the search for more effective candidates has been greatly intensified.

Methods: In this study, the antifibrotic effects and mechanisms of compound PBD-617, the ideal candidate discovered in our previous work, were investigated on transforming growth factor-β1 (TGF-β1)-induced human embryonic lung fibroblasts (HELF) and on bleomycin (BLM)-induced pulmonary fibrotic rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.10.006DOI Listing
December 2018
3 Reads
2.937 Impact Factor

Inhaled calcium salts inhibit tobacco smoke-induced inflammation by modulating expression of chemokines and cytokines.

Pulm Pharmacol Ther 2018 12 22;53:86-99. Epub 2018 Oct 22.

Pulmatrix Inc., 99 Hayden Ave, Suite 390, Lexington, MA 02421, USA. Electronic address:

Tobacco smoke-induced lung inflammation in patients with chronic obstructive pulmonary disease (COPD) worsens with disease progression and acute exacerbations caused by respiratory infections. Chronic therapies to manage COPD center on bronchodilators to improve lung function and inhaled corticosteroids (ICS) to help reduce the risk of exacerbations. Novel therapies are needed that reduce the underlying inflammation associated with COPD and the inflammation resulting from respiratory infections that worsen disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183009
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.10.004DOI Listing
December 2018
14 Reads

Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.

Pulm Pharmacol Ther 2018 12 21;53:80-85. Epub 2018 Oct 21.

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Mucoactive drugs are commonly used in the treatment of acute respiratory tract diseases, such as lower and acute respiratory infection and chronic bronchitis (CB) or chronic obstructive pulmonary disease (COPD) in which an increased mucus secretion is one of main clinical features. Indeed these drugs are designed to promote secretion clearance and to specifically alter the viscoelastic properties of mucus, restoring an effective mucociliary clearance and reducing broncho-obstructive symptoms. In association with mucolytics, these patients frequently also receive antibiotics to reduce the bacterial load, thus decreasing the release of infectious and pro-inflammatory products. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183018
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.10.005DOI Listing
December 2018
26 Reads

Aspirin use and racial differences in Non-Small cell lung cancer survival: What is the plot?

Pulm Pharmacol Ther 2018 12 11;53:79. Epub 2018 Oct 11.

Division of Pediatrics and Neonatology, Moscati Hospital, Via A. Gramsci, 81031, Aversa, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.10.002DOI Listing
December 2018
1 Read

Oncogenic activity of insulin in the development of NSCLC: What is there behind the scenes?

Pulm Pharmacol Ther 2018 12 11;53:78. Epub 2018 Oct 11.

Division of Pediatrics and Neonatology, Moscati Hospital, Via A. Gramsci, 81031, Aversa, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.10.003DOI Listing
December 2018
1 Read

Salvianolic acid B as an anti-emphysema agent I: In vitro stimulation of lung cell proliferation and migration, and protection against lung cell death, and in vivo lung STAT3 activation and VEGF elevation.

Pulm Pharmacol Ther 2018 12 4;53:107-115. Epub 2018 Oct 4.

Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, 410 N. 12th Street, P. O. Box 980533, Richmond, VA, 23298, USA. Electronic address:

Emphysema causes progressive and life-threatening alveolar structural destruction/loss, yet remains irreversible and incurable to date. Impaired vascular endothelial growth factor (VEGF) signaling has been proposed as a new pathogenic mechanism, and if so, VEGF recovery may enable reversal of emphysema. Thus, we hypothesized that salvianolic acid B (Sal-B), a polyphenol in traditional Chinese herbal danshen, is an alveolar structural recovery agent for emphysema by virtue of VEGF stimulation/elevation via activation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3), as stimulating lung cell proliferation and migration, and protecting against lung cell death. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183012
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.10.001DOI Listing
December 2018
8 Reads

Building reliable evidence from real-world data: Needs, methods, cautiousness and recommendations.

Pulm Pharmacol Ther 2018 12 22;53:61-67. Epub 2018 Sep 22.

Center of Healthcare Research & Pharmacoepidemiology, University of Milano-Bicocca, Italy. Electronic address:

National healthcare systems of advanced countries, including Italy, widely agree on the approach whereby public healthcare decisions should be driven by available evidence on effectiveness and safety of therapeutics. It is equally accepted that randomized controlled clinical trials (RCTs), although universally recognised as the most robust "evidence generators", are insufficient for guiding the decision-making process since they are intrinsically unsuited to capture the impact of treatments in routine clinical practice. The complexity of treatments, as well as the demographic and clinical heterogeneity of patients receiving the treatments, and the long period of many treatments, explain the gap between the evidence generated in the controlled, but artificial, setting of RCTs and their current impact in the real world. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.009DOI Listing
December 2018
2 Reads

Andrographolide prevented toluene diisocyanate-induced occupational asthma and aberrant airway E-cadherin distribution via p38 MAPK-dependent Nrf2 induction.

Pulm Pharmacol Ther 2018 12 21;53:39-51. Epub 2018 Sep 21.

Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia. Electronic address:

Toluene diisocyanate (TDI) is a major cause of chemical-induced occupational asthma, which contributes about 15% of global asthma burden. Resistance and compounded side effects associated with the use of corticosteroid in asthma necessitate the search for alternative drugs. Andrographolide (AGP), a naturally occurring diterpene lactone is known to exhibit various bioactivities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.008DOI Listing
December 2018
2 Reads

Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).

Pulm Pharmacol Ther 2018 12 13;53:20-26. Epub 2018 Sep 13.

Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy. Electronic address:

This pooled analysis of double-blind, randomized, placebo-controlled trials aimed to investigate the impact of DOxofylline compaRed tO THEOphylline (DOROTHEO 1 and DOROTHEO 2 studies) on functional and clinical outcomes in asthma. Asthmatic patients ≥16 years of age with forced expiratory volume in 1 s (FEV) ≥50% and <80% and with ≥15% post-bronchodilator increase in FEV were randomized in a 1:1:1:1 ratio in DOROTHEO 1 to receive doxofylline 200 mg, doxofylline 400 mg, theophylline 250 mg, or placebo; in DOROTHEO 2 patients were randomized in a 1:1:1 ratio to receive doxofylline 400 mg, theophylline 250 mg, or placebo. All double-blind treatments were taken orally with immediate release formulations and three times daily. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10945539183018
Publisher Site
http://dx.doi.org/10.1016/j.pupt.2018.09.007DOI Listing
December 2018
26 Reads

Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.

Pulm Pharmacol Ther 2018 12 13;53:33-38. Epub 2018 Sep 13.

AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA. Electronic address:

Background: Chronic obstructive pulmonary disease (COPD) causes significant mortality in Japan. GFF MDI is a long-acting muscarinic antagonist/long-acting β-agonist fixed-dose combination of glycopyrronium (GP) and formoterol fumarate dihydrate (FF), delivered by a metered dose inhaler (MDI) using co-suspension delivery technology, for the long-term maintenance treatment of COPD.

Methods: This randomized, Phase I, single-dose, four-treatment, four-period, crossover study (NCT02196714) examined the pharmacokinetic (PK) and safety profile of two doses of GFF MDI (28. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.005DOI Listing
December 2018
9 Reads

Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.

Pulm Pharmacol Ther 2018 12 11;53:1-5. Epub 2018 Sep 11.

Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University "Magna Græcia" of Catanzaro, Italy. Electronic address:

Mepolizumab is a humanized monoclonal antibody which targets interleukin-5 (IL-5) and is nowadays available in many countries for add-on biological therapy of severe eosinophilic asthma. Although the approval of mepolizumab use in clinical practice has been made possible by several successful pre-marketing controlled trials, so far only a very few studies have been performed in a real-life setting. Within such a context, our present observational investigation refers to 14 patients with refractory eosinophilic asthma, currently treated with mepolizumab at the Respiratory Unit of "Magna Græcia" University Hospital located in Catanzaro, Italy, whose anti-IL-5 treatment began between June 2017 and January 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2018.09.006DOI Listing
December 2018
5 Reads